Core Viewpoint - The acquisition of a 49% stake in Optimed Holding GmbH by Guichuang Tongqiao Medical Technology Co., Ltd. for €18.375 million (approximately RMB 149 million) reflects a strategic move to enhance market presence in Europe and leverage existing distribution networks [1][5]. Group 1: Strategic Logic Behind High Premium Acquisition - Optimed Medizinische Instrumente GmbH, the core operating entity, is a well-established German vascular intervention device company with nearly 30 years of experience in minimally invasive vascular and urological instruments [2][6]. - The acquisition allows Guichuang Tongqiao to access Optimed's distribution network, which spans over 70 countries, facilitating direct access to high-end hospital channels in Europe and avoiding the high costs and compliance risks of building an overseas team [2][6]. - The transaction structure is designed to mitigate initial investment risks, as the target company will not be included in the consolidated financial statements, and Guichuang Tongqiao will provide a €5 million convertible shareholder loan at a 7% annual interest rate while retaining the right of first refusal for the remaining equity [2][6]. Group 2: Synergistic Effects: Technical Complementarity and Manufacturing Upgrade - The collaboration aims to combine German manufacturing capabilities with Chinese R&D efficiency, addressing Guichuang Tongqiao's shortcomings in product refinement through Optimed's expertise in metal processing and precision instrument manufacturing [3][7]. - Guichuang Tongqiao's new innovation base in Zhuhai, expected to generate an output value of RMB 3-4 billion, will help reduce Optimed's product costs through economies of scale [3][7]. - Optimed's proprietary technology for venous diseases will complement Guichuang Tongqiao's arterial intervention product line, with Optimed set to become the exclusive distributor for all vascular products outside China, potentially shortening the time to market by approximately 18 months [3][7]. Group 3: Risks and Challenges: Integration Tests and Valuation Controversies - The absence of performance commitment clauses has raised concerns among some investors regarding the valuation's rationality, as Optimed reported net losses of €864,000, €4.12 million, and €1.25 million for the first three quarters of 2023, 2024, and 2025, respectively, indicating a lack of profitability [4][8]. - Cross-border management challenges exist, as Optimed's CEO Rüdiger Hausherr will remain and report to Guichuang Tongqiao's chairman, necessitating cultural and decision-making alignment [4][8]. - Geopolitical factors, including the EU's recent tightening of medical device regulations (MDR), may pose additional scrutiny on Chinese capital acquisitions of European medical firms, making the balance between global integration and regional autonomy crucial for long-term operations [4][8].

Group 1 - The core point of the article is that Guichuang Tongqiao Medical Technology Co., Ltd. has signed an agreement to acquire shares of Optimed Medizinische Instrumente GmbH in a phased manner, with an option to acquire the remaining shares in the future [2][3] - Optimed, established in 1996, specializes in the research, production, and global sales of minimally invasive vascular and urological medical devices, with a sales and service network covering over 70 countries [2] - The acquisition aims to integrate the commercialization platforms of both companies, enhancing their sales, marketing, and customer service systems to provide high-quality and affordable medical solutions to more patients and doctors [2] Group 2 - The chairman and CEO of Guichuang Tongqiao stated that this acquisition is a significant milestone in the company's internationalization strategy, aiming to strengthen its presence in the European and global markets [3] - The collaboration with Optimed is expected to leverage complementary advantages in product portfolio, production operations, and commercialization platforms, creating an integrated operational platform across China and Europe [3] - The partnership will accelerate clinical trials, post-market follow-up research, and commercialization of related products in international markets, benefiting global healthcare providers and patients [2][3]

Group 1 - The core viewpoint of the article highlights that the optimization of the national procurement rules for medical consumables signals a positive trend towards "anti-involution" and stabilizing expectations, with limited short-term disruption to the industry price system, while benefiting leading companies with strong product capabilities and nationwide supply capacity in the medium to long term [1] - The sixth batch of national centralized procurement for high-value medical consumables will take place on January 13, 2026, involving 12 types of medical consumables, with 496 products from 227 companies bidding, and 440 products from 202 companies selected [1] - The introduction of a "reference price" mechanism aims to rationalize price competition, with 8 out of 20 competitive groups triggering this rule, effectively curbing extreme low-price behaviors by some companies [2] Group 2 - The multi-layer selection rules significantly increased the selection rate, with an overall selection rate of 89% for both companies and products, supporting functional innovation products with reasonable pricing space [3] - The ongoing push for domestic substitution is particularly prominent in the urology intervention sector, with market share increasingly shifting towards domestic companies like Guichuang Tongqiao and Weili [4] - The distribution mechanism strengthens the revenue predictability for leading companies, with different rules corresponding to 70%-100% of demand allocation, which is expected to enhance industry concentration in the medium to long term [5]

Core Viewpoint - Guichuang Tongqiao Medical Technology Co., Ltd. has signed an agreement to acquire shares of Optimed Medizinische Instrumente GmbH, marking a significant milestone in the company's globalization strategy [1] Group 1: Acquisition Details - The acquisition will occur in phases, allowing Guichuang Tongqiao to eventually acquire all remaining shares and corresponding rights of Optimed [1] - This transaction is expected to enhance Guichuang Tongqiao's global operational and delivery capabilities, providing high-quality and affordable innovative products and solutions to more patients [1] Group 2: Global Market Expansion - The deal will support Guichuang Tongqiao's international strategy, accelerating its expansion in Europe and other key overseas markets [2] - Post-transaction, both companies will integrate their commercialization platforms, including sales networks and customer service systems, to create a unified and efficient global operation [2] Group 3: Optimed Overview - Optimed is a German medical technology company focused on minimally invasive vascular and urological intervention devices, established in 1996 and currently serving over 70 countries [3] - The company has a strong reputation in the peripheral venous treatment sector, with its sinus-Venous stent product validated in the STEVECO clinical trial, showing significant improvements in patient quality of life [3] Group 4: Operational Synergies - The acquisition will enhance Guichuang Tongqiao's R&D and manufacturing capabilities in overseas markets, leveraging Optimed's production base in Germany [4] - Both companies will collaborate to improve product quality and operational efficiency, while integrating R&D resources and clinical networks to expedite the launch of clinically valuable innovative products [4] Group 5: Leadership Insights - The Chairman and CEO of Guichuang Tongqiao emphasized that the acquisition is a crucial step in the company's international strategy, aiming to create an integrated operational platform across China and Europe [5] - The CEO of Optimed highlighted the need for a more comprehensive international platform to better serve global customers and achieve long-term growth, noting the complementary strengths of both companies [5]

Core Viewpoint - Guichuang Tongqiao Medical Technology Co., Ltd. has signed an agreement to acquire shares of Optimed Medizinische Instrumente GmbH, marking a significant milestone in the company's globalization strategy [1] Group 1: Acquisition Details - The acquisition will occur in phases, allowing Guichuang Tongqiao to eventually acquire all remaining shares and corresponding rights of Optimed [1] - This transaction is expected to enhance Guichuang Tongqiao's global operational and delivery capabilities, benefiting more patients with high-quality and affordable innovative products [1] Group 2: Global Commercialization Strategy - The deal will support the deep implementation of Guichuang Tongqiao's international strategy, accelerating its expansion in Europe and other key overseas markets [2] - Post-transaction, both companies will integrate their commercialization platforms, including existing sales networks and academic promotion teams, to create a unified and efficient global operation system [2] Group 3: Optimed Overview - Optimed is a German medical technology company focused on minimally invasive vascular and urological intervention devices, established in 1996 and currently serving over 70 countries [3] - The company has a strong reputation in the peripheral venous treatment field, with its sinus-Venous stent product validated in the STEVECO clinical trial, showing significant improvements in patient quality of life compared to conservative treatment [3] Group 4: Operational Synergies - The acquisition will enhance Guichuang Tongqiao's R&D and manufacturing capabilities in overseas markets, leveraging Optimed's production base in Germany to stabilize and efficiently serve European and other key markets [4] - Both companies will collaborate on production and operations to improve product quality and operational efficiency, while integrating R&D resources to expedite the launch of clinically valuable innovative products [4] Group 5: Leadership Insights - The Chairman and CEO of Guichuang Tongqiao emphasized that the acquisition is a crucial step in the company's international strategy, aiming to create an integrated operational platform across China and Europe [5] - The CEO of Optimed highlighted the need for a more comprehensive international platform to better serve global customers and achieve long-term development, noting the complementary strengths between the two companies [5]

Core Viewpoint - The company Guichuang Tongqiao (02190.HK) has entered into an agreement to acquire a 49% stake in E-Med Solutions for approximately €18.375 million (around RMB 149 million), with options to acquire the remaining shares in the future [1][2]. Group 1: Acquisition Details - The acquisition agreement was signed on January 16, 2026, with the company acting as the buyer and E-Med Solutions as the seller [1]. - The total consideration for the acquisition is subject to further adjustments [1]. - The target company, Optimed Holding GmbH, is a limited liability company established under German law and is currently wholly owned by the seller [2]. Group 2: Target Company Overview - Optimed Holding GmbH and its subsidiaries, including Optimed Medizinische Instrumente GmbH, focus on the development, manufacturing, and distribution of medical technology products and solutions [2]. - The main operating subsidiary, Optimed Medizinische Instrumente GmbH, is headquartered in Germany and specializes in high-quality medical products for minimally invasive vascular and urological instruments [2]. - Optimed has a comprehensive product portfolio in the peripheral venous stent market, including devices for the iliac vein, iliac artery bifurcation, inferior vena cava, and aorta [2]. Group 3: Strategic Implications - Following the completion of the acquisition, the company and the target company will integrate their commercialization platforms, including sales and marketing networks, promotional capabilities, and customer service infrastructure [2]. - The target company will serve as the exclusive distributor for all vascular products outside of mainland China [2]. - Rüdiger Hausherr will continue as CEO of Optimed and report to Dr. Zhao Zhong, the company's chairman and CEO, which is expected to enhance and accelerate the company's international sales capabilities and global expansion [2].

Core Viewpoint - The company has entered into an agreement to acquire a 49% stake in Optimed Holding GmbH for approximately €18.375 million, marking a significant step in its global expansion strategy [1]. Group 1: Acquisition Details - The acquisition agreement allows the company to purchase 49% of Optimed Holding GmbH, with an option to acquire the remaining shares from other shareholders [1]. - Post-acquisition, Optimed will not become a subsidiary, and its financial performance will not be consolidated into the company's financial statements [1]. Group 2: Strategic Benefits - The acquisition represents a key milestone in the company's long-term commitment to global expansion, enhancing its competitive position and influence in international markets [1]. - Integration with Optimed's sales network will accelerate the global application of innovative vascular solutions, leveraging strong relationships with European medical experts [2]. - The transaction is expected to create significant manufacturing and operational synergies between Germany and China, improving product quality and operational efficiency [2]. - The company aims to fully leverage its R&D capabilities through an integrated global commercialization platform, providing advanced medical solutions to patients and healthcare professionals worldwide [2]. Group 3: Operational Integration - Following the acquisition, the company and Optimed will integrate their commercialization platforms, including sales and marketing networks, enhancing international sales capabilities [3]. - Optimed will serve as the exclusive distributor for all vascular products in markets outside of mainland China [3]. - Rüdiger Hausherr will continue as CEO of Optimed, reporting to the company's Chairman and CEO, Dr. Zhao Zhong, which will further accelerate the company's global expansion efforts [3].

Core Viewpoint - The acquisition of a 49% stake in Optimed Holding GmbH by the company marks a significant milestone in its long-term commitment to global expansion and aims to enhance its competitive position in the international market [1][2]. Group 1: Acquisition Details - The company has entered into a purchase agreement to acquire 49% of Optimed Holding GmbH for approximately €18.375 million [1]. - The agreement includes an option for the company to acquire the remaining shares from other shareholders at its discretion [1]. - Post-acquisition, Optimed will not become a subsidiary of the company, and its financial performance will not be consolidated into the company's financial statements [1]. Group 2: Strategic Benefits - The acquisition is a key milestone for the company's entry into the European and global markets, facilitating asset integration to accelerate international strategy deployment and diversify the product portfolio [2]. - The integration with Optimed's sales network will enhance the global application of innovative vascular solutions, leveraging strong relationships with European medical experts to expedite clinical processes and product launches [2]. - The transaction is expected to create significant manufacturing and operational synergies between Germany and China, improving product quality and operational efficiency while expanding production capacity in Germany [2]. Group 3: R&D and Commercialization - The integrated global commercialization platform will fully leverage the company's R&D capabilities, aiming to provide cutting-edge medical solutions to patients and healthcare professionals worldwide [3]. - Following the acquisition, the company and Optimed will integrate their commercialization platforms, including sales and marketing networks, enhancing international sales capabilities [3]. - Optimed will serve as the exclusive distributor for all vascular products in markets outside mainland China, with Rüdiger Hausherr continuing as CEO of Optimed [3].

Core Viewpoint - The company is set to acquire a 49% stake in Optimed Holding GmbH for approximately €18.375 million, marking a significant step in its global expansion strategy and enhancing its competitive position in the medical technology sector [1][2]. Group 1 - The acquisition represents a key milestone in the company's long-term commitment to global expansion, facilitating entry into European and global markets [2]. - The integration of assets is expected to accelerate the company's international strategy, diversify its product portfolio, and expand its global distribution network [2]. - The transaction aims to create significant manufacturing and operational synergies between Germany and China, enhancing product quality and operational efficiency [2]. Group 2 - The acquisition will enable the company to fully leverage its efficient R&D capabilities, expanding its innovative solutions to global markets [3]. - Post-acquisition, the company and Optimed will integrate their commercialization platforms, including sales and marketing networks, to enhance international sales capabilities [3]. - Optimed will serve as the exclusive distributor for all vascular products in markets outside of mainland China, significantly boosting the company's international sales efforts [3].

Zylox-Tonbridge Medical Technology Co., Ltd. 歸創通橋醫療科技股份有限公司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：2190） 須予披露交易 收購目標公司之49%股權 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 緒言 於 2026 年 1 月 16 日（交 易 時 段 前，香 港 時 間），本 公 司（作 為 買 方）與E-Med Solutions（作為賣方）訂立買賣協議。根據買賣協議，買方同意收購目標公司 之49%股權，總代價約為18.375百萬歐元（相當於人民幣149.41百萬元）（可予進 一步調整）。根據買賣協議，買方亦獲授期權，可由買方酌情行使，以向目 標公司其他股東收購目標公司之餘下股權。 建議收購事項完成後，目標公司將不會成為本公司之附屬公司，且目標公司 之財務業績將不會併入本公司之財務報表。 上市規則之涵義 由於有關買賣協議項下擬進 ...